Price ambition is only defensible when the evidence can carry it Manufacturers can no longer r...
Read moreEvery payer ultimately asks the same question: “Compared with what?” This single question shapes...
Read moreOptimising evidence generation in trial design, while navigating regulatory and local payer requirem...
Read moreNegotiations between the Trump administration and pharmaceutical companies on lowering U.S...
Read moreSuccessfully navigating early payer scientific advice whether through Joint Scientific Consultations...
Read moreProving the long-term value of pharmaceutical assets remains one of the biggest challenges for manuf...
Read moreThe key to pricing success for any pharmaceutical product is effectively exhibiting the asset’...
Read moreExecutive Summary What Has Changed in the Pharma Package? The Council’s agreed text on the Pha...
Read moreWhether you’re in drug development, market access, or health economics, early scientific advic...
Read moreCharlie Hewitt from Remap Consulting initiated today’s session by providing a description of the c...
Read more